Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Recruiting Not applicable

Interest of Walking Sticks to Increase Walking Activity of People With Sagittal Imbalance of Spine

NCT07127250 · tracked via the Priya Life Science France tracker
Phase
Not applicable
Started
2025-11-25
Last updated
2026-04-03

Condition(s) studied

Static Spinal Disorder

Investigational drug(s) / intervention(s)

Walking sticks

Walking sticks: Walking with walking sticks and pedometer Daily walking activity recorded in a logbook

Study summary

The purpose of this pilot study is to assess the impact of using walking sticks on walking perimeter in people with anterior spinal imbalance.

Eligibility

Sex
ALL
Min age
50 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Adult ≥ 50 years * VAS (Sagittal Vertical Axis, C7-S1, EoS (clinical follow-up)) \> 5cm * Able to do transfers alone * Able to walk 10 minutes or 400 meters in a row * Self-reported Walking difficulties * Person living at home * Person willing and consenting to participate in the study * Health insurance Exclusion Criteria: * Current use of walking sticks * Advanced and symptomatic osteoarthritis of the lower limbs * Static disorder of the fixed spine * Introduction of a straightening brace in the 3 months preceding the start of the study * Static disorder explained by infectious, tumoral, congenital or neurodegenerative pathologies * Uncompensated lower-limb length inequality (\> 2cm) * Lower limb motor deficit * Upper limb pathology preventing cane use * Proprioceptive or vestibular pathology * Inability to write, speak or read French * Cognitive and/or behavioral disorders * Participation in other research on spinal balance and/or gait, or that could influence these factors during the study period * People under tutorship or curatorship * Free state medical assistance

Primary outcome measure(s)

  • Walking perimeter — Day 0 and month 3 (+ 15 days, 13 to 15 weeks)
    6-minute walk test at Day 0 without walking sticks and 3 months later with walking sticks

Trial sites (1)

FacilityCityRegionStatus
Service de rééducation et de réadaptation de l'appareil locomoteur et des pathologies du rachis.Hôpital Cochin Paris France Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07127250 on ClinicalTrials.gov ↗ ← All trials in France